Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Raine

Showing results (41-50 of 107) with videos related to

Pageof 11
Sort By:
Crohn'S & Colitis 360|July 11, 2026
Mirikizumab is equally effective in ustekinumab-exposed and ustekinumab-naïve patients with UC: a multicenter real-world cohortMohmmed Tauseef Sharip, Dharmaraj Durai, Eva Vayreda, et al.
Nature Communications|November 6, 2024
Fine-mapping and molecular characterisation of primary sclerosing cholangitis genetic risk lociElizabeth C Goode, Laura Fachal, Nikolaos Panousis, et al.
Journal of Crohn'S & Colitis|September 7, 2024
Differences in the Adverse Event Burden of Corticosteroid Use in Inflammatory Bowel Disease as Reported Between Adverse Event Reporting Systems and a Patient QuestionnaireEman Al Sulais, Edouard Louis, Bernd Bokemeyer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 29, 2011
Cutting Edge: Regulator of G protein signaling-1 selectively regulates gut T cell trafficking and colitic potentialDeena L Gibbons, Lucie Abeler-Dörner, Tim Raine, et al.
Journal of Crohn'S & Colitis|June 23, 2021
ECCO Topical Review: Refractory Inflammatory Bowel DiseaseTim Raine, Bram Verstockt, Uri Kopylov, et al.
Pragmatic and Observational Research|March 20, 2024
Trends in Systemic Glucocorticoid Utilization in the United Kingdom from 1990 to 2019: A Population-Based, Serial Cross-Sectional AnalysisAndrew N Menzies-Gow, Trung N Tran, Brooklyn Stanley, et al.
Rheumatology (Oxford, England)|February 23, 2024
Impact on patient outcomes of spondyloarthritis-inflammatory bowel disease multi-disciplinary meetingsSarah Sayers, Danielle Lam, Qutab Shah, et al.
BMJ Open|February 18, 2019
Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trialMartin Geoffrey Thomas, Carrie Bayliss, Simon Bond, et al.
Frontline Gastroenterology|June 27, 2020
Practice pattern variability in the management of acute severe colitis: a UK provider surveyShaji Sebastian, Jessica Lisle, Sreedhar Subramanian, et al.
Journal of Crohn'S & Colitis|April 14, 2026
Real-world patient characteristics, treatments, and outcomes during and after severe ulcerative colitis hospitalizationTim Raine, James D Lewis, Gareth C Parkes, et al.
Pageof 11

Showing results (41-50 of 107) with videos related to

Sort By:
Pageof 11
Crohn'S & Colitis 360|July 11, 2026
Mirikizumab is equally effective in ustekinumab-exposed and ustekinumab-naïve patients with UC: a multicenter real-world cohortMohmmed Tauseef Sharip, Dharmaraj Durai, Eva Vayreda, et al.
Nature Communications|November 6, 2024
Fine-mapping and molecular characterisation of primary sclerosing cholangitis genetic risk lociElizabeth C Goode, Laura Fachal, Nikolaos Panousis, et al.
Journal of Crohn'S & Colitis|September 7, 2024
Differences in the Adverse Event Burden of Corticosteroid Use in Inflammatory Bowel Disease as Reported Between Adverse Event Reporting Systems and a Patient QuestionnaireEman Al Sulais, Edouard Louis, Bernd Bokemeyer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 29, 2011
Cutting Edge: Regulator of G protein signaling-1 selectively regulates gut T cell trafficking and colitic potentialDeena L Gibbons, Lucie Abeler-Dörner, Tim Raine, et al.
Journal of Crohn'S & Colitis|June 23, 2021
ECCO Topical Review: Refractory Inflammatory Bowel DiseaseTim Raine, Bram Verstockt, Uri Kopylov, et al.
Pragmatic and Observational Research|March 20, 2024
Trends in Systemic Glucocorticoid Utilization in the United Kingdom from 1990 to 2019: A Population-Based, Serial Cross-Sectional AnalysisAndrew N Menzies-Gow, Trung N Tran, Brooklyn Stanley, et al.
Rheumatology (Oxford, England)|February 23, 2024
Impact on patient outcomes of spondyloarthritis-inflammatory bowel disease multi-disciplinary meetingsSarah Sayers, Danielle Lam, Qutab Shah, et al.
BMJ Open|February 18, 2019
Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trialMartin Geoffrey Thomas, Carrie Bayliss, Simon Bond, et al.
Frontline Gastroenterology|June 27, 2020
Practice pattern variability in the management of acute severe colitis: a UK provider surveyShaji Sebastian, Jessica Lisle, Sreedhar Subramanian, et al.
Journal of Crohn'S & Colitis|April 14, 2026
Real-world patient characteristics, treatments, and outcomes during and after severe ulcerative colitis hospitalizationTim Raine, James D Lewis, Gareth C Parkes, et al.
Pageof 11